- Home
- LNG vs REGN Comparison
LNG vs REGN Comparison
Compare LNG & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNG
- REGN
- Stock Information
- Founded
- LNG 1983
- REGN 1988
- Country
- LNG United States
- REGN United States
- Employees
- LNG N/A
- REGN N/A
- Industry
- LNG Oil/Gas Transmission
- REGN Biotechnology: Pharmaceutical Preparations
- Sector
- LNG Utilities
- REGN Health Care
- Exchange
- LNG Nasdaq
- REGN Nasdaq
- Market Cap
- LNG 52.1B
- REGN 59.5B
- IPO Year
- LNG 1997
- REGN 1991
- Fundamental
- Price
- LNG $235.69
- REGN $573.38
- Analyst Decision
- LNG Strong Buy
- REGN Buy
- Analyst Count
- LNG 13
- REGN 23
- Target Price
- LNG $262.77
- REGN $794.83
- AVG Volume (30 Days)
- LNG 1.6M
- REGN 996.9K
- Earning Date
- LNG 10-30-2025
- REGN 10-30-2025
- Dividend Yield
- LNG 0.85%
- REGN 0.61%
- EPS Growth
- LNG N/A
- REGN 5.03
- EPS
- LNG 17.11
- REGN 39.67
- Revenue
- LNG $18,231,000,000.00
- REGN $14,214,200,000.00
- Revenue This Year
- LNG $33.66
- REGN N/A
- Revenue Next Year
- LNG $12.70
- REGN $4.97
- P/E Ratio
- LNG $13.77
- REGN $14.45
- Revenue Growth
- LNG 14.42
- REGN 5.38
- 52 Week Low
- LNG $175.14
- REGN $476.49
- 52 Week High
- LNG $257.65
- REGN $1,175.16
- Technical
- Relative Strength Index (RSI)
- LNG 48.16
- REGN 51.26
- Support Level
- LNG $239.29
- REGN $559.62
- Resistance Level
- LNG $243.50
- REGN $588.70
- Average True Range (ATR)
- LNG 4.51
- REGN 17.58
- MACD
- LNG -0.08
- REGN -2.29
- Stochastic Oscillator
- LNG 45.26
- REGN 27.07
About LNG Cheniere Energy Inc.
Cheniere Energy is a liquified natural gas, or LNG, producer with two facilities in Corpus Christi, Texas and Sabine Pass, Louisiana. It generates most of its revenue through long-term contracts with customers on a fixed and variable fee payout structure. It also generates revenue by selling uncontracted LNG to customers on a short or one-time basis. A subsidiary, Cheniere Energy Partners, owns the Sabine Pass facility and trades as a master limited partnership.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).